Moderna company headlines, earnings, strategy, leadership, and market-moving business updates.
Market data may be delayed. For informational purposes only. Not investment advice.
Ahead of its next quarterly results, Moderna is drawing attention for potential regulatory developments around mRNA-1010 and the company’s commercialization plan, both of which investors say could influence the durability of its post-Covid growth story.
THE APEX TIMES
THE APEX TIMES
Moderna (MRNA) ended the latest trading day at $66.98, down 1.89% from its prior close, according to Yahoo Finance.
THE APEX TIMES
The Cambridge, Massachusetts biotech said it will report second-quarter 2026 financial results with a live call and webcast set for 8:00 a.m. ET.
THE APEX TIMES
The contract is tied to growing demand for protection against respiratory syncytial virus, which can lead to severe lower-respiratory disease. Moderna has not disclosed key terms in the post highlighted by the report, including pricing and delivery timing.
THE APEX TIMES
Moderna’s stock has surged this year, but a market valuation check suggests the shares may still be pricing in substantial future progress, with investors weighing growth enthusiasm against what looks like a lack of “margin of safety.”
THE APEX TIMES
Moderna’s stock jumped after a European Commission procurement deal tied to a respiratory vaccine raised expectations for additional demand.
THE APEX TIMES
Moderna and two other biotech names were hit hard on July 10, despite the absence of clearly identified negative catalysts in the report, underscoring how quickly sentiment can swing in a crowded 2026 rally.
THE APEX TIMES
In a broad risk-on session, the Dow Jones ended higher while SK Hynix jumped after starting U.S. trading. Moderna shares declined, according to a market wrap published Friday.
THE APEX TIMES
A Yahoo Finance report says Moderna and Takeda are trying again for FDA approval this summer, while Capricor is working to turn its position in a new sleep treatment into a commercial foothold.
